Optimizing Surgical Transplant of CFTR Gene-Corrected Human Basal Stem Cells to the Upper Airway
优化 CFTR 基因校正的人类基底干细胞至上呼吸道的手术移植
基本信息
- 批准号:10361467
- 负责人:
- 金额:$ 47.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-03-01 至 2026-01-31
- 项目状态:未结题
- 来源:
- 关键词:AirAirway DiseaseAnimal ModelAnion Transport ProteinsAnionsArchitectureAutologousBehaviorBicarbonatesBiocompatible MaterialsBiological AssayBiological ModelsCRISPR correctionCRISPR/Cas technologyCell CountCell Differentiation processCell FractionCell SurvivalCell TherapyCell TransplantationCellsChimerismChloridesClustered Regularly Interspaced Short Palindromic RepeatsCoculture TechniquesCollagenCollagen Type ICystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDelta F508 mutationDevelopmentDifferentiated GeneDiscriminationElectrolytesEngineeringEngraftmentEpidermal Growth FactorEpithelialEpithelial CellsFDA approvedFamily suidaeFunctional disorderGreen Fluorescent ProteinsGrowth FactorHeparin BindingHumanImmuneImmunohistochemistryIn VitroInfiltrationInflammationLife ExpectancyLiquid substanceLuciferasesLungMaxillary SinusMeasuresMediatingMedicalMembraneMendelian disorderMethodsMicrosurgeryModalityModelingMucous body substanceMusMutationOperative Surgical ProceduresOutcomePathologicPatientsPatternPhysiciansProteinsPublishingRegulator GenesRespiratory FailureRespiratory SystemRespiratory Tract InfectionsRodentRodent ModelScientistSinusSiteSmall Intestinal SubmucosaStem cell transplantStromal CellsSurgical ModelsSystemTechnologyTestingTimeTissuesTranslatingTranslationsTransplantationVX-770Waterairway epitheliumbasebehavior in vitrobioluminescence imagingcell behaviorcell replacement therapycystic fibrosis airway epitheliacystic fibrosis patientsdisease-causing mutationexperimental studygene correctiongenome editinghuman stem cellsimmunosuppressedimprovedin vivoin vivo engraftmentinnovationmigrationmouse modelnovelpersonalized strategiespre-clinicalprotein expressionrecruitrecurrent infectionreplacement tissuerestorationscaffoldstem cell expansionstem cell proliferationstem cell replacementstem cell therapystem cellssuccesssymptom treatmenttreatment strategy
项目摘要
PROJECT SUMMARY/ABSTRACT
Cystic fibrosis (CF) is an autosomal recessive single-gene disease caused by mutations in the cystic fibrosis
transmembrane conductance regulator (CFTR) gene. The most common mutation, termed ∆F508, occurs in
~85% of CF patients. Because the CFTR gene encodes for an anion transport protein, CFTR mutations alter
electrolyte and water transport, resulting in dense, pathologic, mucous and other secretions. The most
harmful effects of CFTR dysfunction occur in the respiratory system, with recurrent infections and
inflammation of the upper and lower airways. Despite substantial progress with medical therapies, there
remains a tremendous unmet need for improved, durable therapies for CF.
For the past 3 years, our collaborative group of complementary scientists and physicians has determined to
develop a novel, stem cell-based treatment strategy for patients suffering from CF. For several critical
reasons, we directed our efforts to cell-based therapy of CF upper airway disease using ex vivo-expanded,
primary human airway basal stem cells, termed ABCs. The first major milestone was to utilize CRISPR/Cas9
genome editing technology to efficiently correct the ∆F508 mutation in ABCs cultured from CF patients
undergoing sinus surgery. This gene correction approach has led to significant restoration of chloride anion
transport from 0-3% to 30-40% in ABCs. This encouraging, and newly published, development now provides
a pre-clinical roadmap for re-introducing CFTR gene-corrected ABCs into in vivo contexts as a stem cell
replacement therapy.
In this proposal, we will rigorously determine the most efficient, biomaterial platform for ex vivo-to-in vivo
transplant and engraftment of human ABCs, and assess the behavior of gene-corrected ABCs in the lab and
live animal model using a microsurgical model system of upper airway transplantation that we have
developed. The experiments outlined are essential pre-clinical steps in order to translate this approach to CF
patients to generate an innovative and possibly transformative therapy for patients with CF, and the first stem
cell-based therapy for human airway disease.
项目总结/摘要
囊性纤维化(CF)是一种常染色体隐性单基因疾病,
跨膜传导调节因子(CFTR)基因。最常见的突变,被称为IF 508,发生在
约85%的CF患者。由于CFTR基因编码阴离子转运蛋白,CFTR突变改变了
电解质和水的运输,导致致密,病理,粘液和其他分泌物。最
CFTR功能障碍的有害影响发生在呼吸系统中,伴随复发性感染,
上下呼吸道的炎症。尽管医学治疗取得了重大进展,
对于CF的改进的、持久的疗法仍然存在巨大的未满足的需求。
在过去的3年里,我们的互补科学家和医生的合作小组已经决定,
为患有CF的患者开发一种新的基于干细胞的治疗策略。对于几个关键的
出于各种原因,我们将努力方向定为使用离体扩增的CF上呼吸道疾病的基于细胞的治疗,
原代人气道基底干细胞,称为ABC。第一个重要的里程碑是利用CRISPR/Cas9
基因组编辑技术,以有效纠正CF患者培养的ABC中的BNF 508突变
接受鼻窦手术这种基因校正方法导致氯阴离子的显著恢复
从0-3%运输到ABC中的30-40%。这一令人鼓舞的、新公布的发展现在提供了
将CFTR基因校正的ABC作为干细胞重新引入体内环境的临床前路线图
替代疗法
在这项提案中,我们将严格确定最有效的生物材料平台,
人ABC的移植和植入,并在实验室中评估基因校正的ABC的行为,
活体动物模型,使用显微外科模型系统的上气道移植,我们有
开发为了将这种方法转化为CF,所概述的实验是必要的临床前步骤
为CF患者提供一种创新的、可能是变革性的治疗方法,
用于人类气道疾病的基于细胞的疗法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jayakar V Nayak其他文献
Jayakar V Nayak的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jayakar V Nayak', 18)}}的其他基金
Optimizing Surgical Transplant of CFTR Gene-Corrected Human Basal Stem Cells to the Upper Airway
优化 CFTR 基因校正的人类基底干细胞至上呼吸道的手术移植
- 批准号:
10548833 - 财政年份:2021
- 资助金额:
$ 47.01万 - 项目类别:
相似海外基金
EXposomic Profiling in Airway disease to uNravel Determinants of disease in Asthma (EXPAND-Asthma) Center
气道疾病暴露组分析以解开哮喘疾病的决定因素 (EXPAND-Asthma) 中心
- 批准号:
10744673 - 财政年份:2023
- 资助金额:
$ 47.01万 - 项目类别:
Bacteriophage as a predictive biomarker in chronic Pseudomonas airway disease
噬菌体作为慢性假单胞菌气道疾病的预测生物标志物
- 批准号:
10723956 - 财政年份:2023
- 资助金额:
$ 47.01万 - 项目类别:
Defining a gene expression signature of airway disease, COPD exacerbations, and response to treatment
定义气道疾病、COPD 恶化和治疗反应的基因表达特征
- 批准号:
10733573 - 财政年份:2023
- 资助金额:
$ 47.01万 - 项目类别:
Impact of Maternal Arsenic Exposure on Offspring's Epigenetic Reprogramming of Allergic Airway Disease
母亲砷暴露对后代过敏性气道疾病表观遗传重编程的影响
- 批准号:
10733607 - 财政年份:2023
- 资助金额:
$ 47.01万 - 项目类别:
Immune Mediators of IL-22 Signaling Alter Allergic Airway Disease
IL-22 信号的免疫介质改变过敏性气道疾病
- 批准号:
10853347 - 财政年份:2023
- 资助金额:
$ 47.01万 - 项目类别:
The role of anaerobic microbiota in cystic fibrosis airway disease trajectory
厌氧微生物群在囊性纤维化气道疾病轨迹中的作用
- 批准号:
10716654 - 财政年份:2023
- 资助金额:
$ 47.01万 - 项目类别:
Microbial adaptation of Pseudomonas lipid A structure in CF airway disease progress
假单胞菌脂质 A 结构在 CF 气道疾病进展中的微生物适应
- 批准号:
10722599 - 财政年份:2023
- 资助金额:
$ 47.01万 - 项目类别:
The role of anaerobic microbiota in cystic fibrosis airway disease trajectory
厌氧微生物群在囊性纤维化气道疾病轨迹中的作用
- 批准号:
10985906 - 财政年份:2023
- 资助金额:
$ 47.01万 - 项目类别:
Mentoring patient-oriented researchers in inflammatory airway disease
指导炎症性气道疾病领域以患者为中心的研究人员
- 批准号:
10657746 - 财政年份:2022
- 资助金额:
$ 47.01万 - 项目类别:














{{item.name}}会员




